Press Release

Seoul, Korea and Sydney, Australia – 29 April 2019 | Access Bio Inc. and Atomo Diagnostics today announced that they have developed a best-in-class rapid diagnostic test (RDT) for screening for hepatitis C virus (HCV). The companies have also collaborated to create a version for professional...

SYDNEY, Australia,4 April 2019 | Award-winning medical device developer Atomo Diagnostics today announced that its Atomo HIV Self Test – the first and only diagnostic self-test for HIV that has been formally reviewed and approved by the Therapeutic Goods Administration (TGA) – is now available to the Australian public.  The...

SYDNEY, Australia,29 November 2018: Award-winning medical device developer Atomo Diagnostics today announced that its Atomo HIV Self Test has been approved for sale in Australia by the Therapeutic Goods Administration (TGA).  It is the first and only diagnostic self-test for HIV to have received approval from Australia’s national regulator.   HIV self‑testing is the process whereby...

HERTFORDSHIRE, England, PITTSBURGH and SYDNEY, September 24, 2018 – Global pharmaceutical company Mylan N.V.(NASDAQ: MYL) and medical device company Atomo Diagnostics today announced a strategic partnership to commercialize CE-Marked in vitro HIV rapid diagnostic tests for self-testing in low- and middle-income countries. The tests will allow...

Sydney, Australia and Woodstock, England – 05 June 2018 | Atomo Diagnostics and Owen Mumford Ltd have today announced a strategic partnership for commercialisation of innovative HIV rapid tests in European markets Owen Mumford acquires exclusive rights to Atomo’s HIV rapid tests for commercialisation under...

RPS Diagnostics partners with Atomo Diagnostics to develop next generation FebriDx blood tests for antibiotic stewardship in the outpatient setting Sarasota, Florida and Sydney, Australia (February 20, 2018) – United States biotechnology company, RPS Diagnostics (RPS®), and Australian medical device company, Atomo Diagnostics, announced today that...

Sydney, Australia and Seoul, South Korea – 23 January 2018 | Atomo Diagnostics and Access Bio Inc. today announce a strategic partnership to leverage the respective strengths of both innovative rapid diagnostic test (RDT) companies to expand point of care HIV testing in global markets. ...

Sydney, Australia, 7 December 2017 | Atomo Diagnostics, the world leader in integrated point-of-care rapid diagnostic devices, announced today that its Atomo HIV Self Test has been confirmed as eligible for procurement by organisations entitled to access Global Fund and Unitaid resources. Atomo HIV Self...

SYDNEY, AUSTRALIA, October 10, 2017 – Atomo Diagnostics, a world leader in innovative point-of-care, rapid diagnostic devices, announced today that its Atomo HIV Self Test has been granted CE Marking by a European Union Notified Body. Atomo HIV Self Test granted CE Mark; will facilitate...

Sydney, Australia, May 30, 2017| Multi-award winning medical device innovator Atomo Diagnostics today announced its pioneering HIV self test product has been approved for sale in Kenya. Following successful product evaluations and in-field studies conducted in Kenya by investigators from the Kenya Medical Research Institute (KEMRI), Nairobi, Atomo...

SYDNEY, Australia, 1 February  2017: Medical device innovator Atomo Diagnostics today announced it had received US$1 million (A$1.31 million, C$1.32 million) in financing from Grand Challenges Canada to support its continued business operations. Funded by the Government of Canada, Grand Challenges Canada is dedicated to supporting Bold...

Guipry, France and Sydney, Australia, 8 November 2016 - French biotechnology company, NG Biotech, and Australian medical device innovator, Atomo Diagnostics, announced today that they have developed the world’s first fully-integrated blood-based rapid test for detection of hCG levels in pregnancy. The new product, NG-Test®...

SYDNEY, Australia 11 August 2016 | Medical device innovator Atomo Diagnostics today announced it had raised A$4.5 million in new equity funding from a number of professional investors including the New York-based Global Health Investment Fund (GHIF), as well as a company associated with former...

Global Health Investment Fund Provides Capital to Atomo Diagnostics Backing of social impact investment fund will finance scale-up of Australian medical device company’s award-winning rapid diagnostic HIV test and launch of an affordable HIV self-test offering unmatched performance NEW YORK & SYDNEY–(BUSINESS WIRE) | The Global Health...

  Cape Town, South Africa | The Desmond Tutu HIV Foundation has successfully completed an acceptability and usability study on HIV self-testing using the Atomo HIV Self Test. With 224 participants enrolled, the study provides valuable information into one potential avenue to rapidly expand HIV testing...

Chicago, USA – July 30, 2014 | Atomo Diagnostics is introducing the world’s first integrated rapid blood test device to the USA market at the 2014 AACC Annual Meeting & Clinical Lab Expo (July 27-31) following a successful presentation at the 20th International AIDS Conference...

Sydney, Australia – July 22, 2014 | Atomo Diagnostics today presented the leading Australian HIV diagnostics self-test device at the 20th International AIDS Conference 2014 in Melbourne today (July 20 -25, 2014). Atomo Diagnostics is participating in the ‘Realising Potential for HIV Self-testing’ conference session organized...